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Summary 
Objectives
Compared to the general population, patients with major men-
tal disorders have a higher prevalence of metabolic syndrome 
(MetS), which is known to increase cardiovascular risk and mor-
tality. Many factors contribute to development and maintenance 
of metabolic disturbances in psychiatric patients. Nevertheless, 
gaps remain in relevant aspects, encouraging further studies in 
specific subgroups to evaluate the impact of each variable in 
developing MetS. Our aim is to identify the clinical and sociode-
mographic features consistently associated with the occurrence 
of MetS in a sample of inpatients affected by severe and acute 
mental illness.
Methods
Our study had a naturalistic design and involved inpatients 
consecutively admitted to the Psychiatric Unit of ‘S Luigi 
Gonzaga Hospital’ of Orbassano from December 2013 to 
September 2014. At study entry, general sociodemograph-
ic and clinical information was collected for each subject, 
including lifestyles and comorbidity for cardiovascular dis-
eases and diabetes. Through index visit and routine blood 
exam, all metabolic parameters were assessed to define the 
presence of MetS according to NCEP ATP III modified crite-
ria. Sociodemographic and clinical correlates of MetS were 
then investigated.
Results
One hundred twenty-five patients were enrolled. Of these, 37 
(29.6%) had schizophrenia spectrum and other psychotic disor-
ders, 47 (37.6%) had bipolar and related disorders, 28 (22.4%) 
had depressive disorders and 13 (10.4%) had personality dis-
orders. 
MetS was present in 35.2% of the sample. Low HDL-C levels 
were the most frequently endorsed criterion, present in 57.6% 
of subjects. Abdominal obesity, high triglycerides, hypertension 
and fasting hyperglycaemia were observed in 51.2%, 30.4%, 
28.8% and 20% of patients, respectively. Patients who fulfilled 
MetS definition were more often characterised by current atypical 
antipsychotic treatment, current alcohol abuse, current psychiatric 
comorbidity with substance related disorders and longer duration 
of illness. After performing regression analysis, only current atypi-
cal antipsychotic treatment was significantly associated to MetS. 
Conclusions
Our study confirms the increased risk of MetS in patients treated 
with atypical antipsychotics. No other clinical or sociodemo-
graphic variables were associated with MetS. These findings sug-
gest a shared susceptibility to antipsychotic-related metabolic 
dysregulation that is not primarily related to psychiatric diagnosis 
or concomitant to other psychiatric treatment. 
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Introduction
Patients with major mental disorders are subject to pre-
mature death from all causes compared to the general 
population 1. Among causes of death, cardiovascular (CV) 
disease is responsible for as much as 50% of excess mor-
tality. The association between CV risk and major mental 
disorders such as bipolar disorder and schizophrenia is 
well established and comparable  2-4. Furthermore, indi-
viduals with unipolar major depression have levels of CV 
risk that are at least as high as those in patients who suffer 
from bipolar disorder 5 6.
There are many reasons why patients with mood and psy-
chotic disorders have elevated CV risk, but one source 
of CV risk, which is overrepresented in this population, 
is the cluster of findings that define metabolic syndrome 
(MetS) 7-10. 
More specifically, MetS occurs in nearly one-third of pa-
tients with schizophrenia  11  12, while 37.3% of patients 
with bipolar disorder develop MetS, which is nearly twice 
the rate in the general population 13 14. 
Many factors contribute to development and maintenance 
of MetS in psychiatric patients including poor lifestyle 
choices, such as excessive caloric and cholesterol intake, 
cigarette smoking and physical inactivity 15 16. Moreover, 
major psychiatric disorders have been related to genetic 
liability and lifelong use of medications such as antipsy-
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Assessments and procedures
At study entry, general sociodemographic and clinical in-
formation was collected for each subject. Lifestyles were 
also investigated in the study sample: information about 
exposure to cigarette smoking, duration of alcohol and 
drug consumption and physical activity was obtained by 
directly interviewing patients. A score was assigned to the 
intensity of physical activity: absent, mild (<  4 h/week), 
moderate (4 h/week) and intense (> 4 h/week, regular) 23. 
Comorbidity and family history for diabetes or cardiovas-
cular diseases and current treatments for hypertension, 
diabetes or dyslipidaemia were assessed by looking at 
medical reports and by directly interviewing patients. At 
index visit, weight, height, waist circumference and blood 
pressure were measured. Weight was measured with the 
participant undressed and fasting height was measured 
barefoot. Waist circumference, measuring central adipos-
ity, was measured midway between the inferior margin of 
the ribs and the superior border of the iliac crest, at mini-
mal respiration. Two blood pressure measurements were 
obtained by using a mercury sphygmomanometer: the first 
with the subject in a supine position and the second with 
the subject in a seated position at least 2 min after the first 
measurement. The mean blood pressure of the two meas-
urements was used. All the procedures were performed by 
the attending physician in the hospital setting.
A blood draw for routine blood exam was performed 
upon hospital admission, as part of routine clinical man-
agement. At the time when blood was drawn, patients 
were fasting for the previous 10 h; patients who did not 
fast were rescheduled. Blood exams included assessment 
of the following: glucose, total cholesterol, triglycerides, 
LDL and HDL-C. Patients were stated to have MetS if they 
endorsed at least three of the following five criteria, ac-
cording to NCEP ATP III modified criteria:
•  abdominal obesity: waist circumference ≥ 102 cm in 
men and ≥ 88 cm in women;
•  hypertriglyceridaemia: ≥ 150 mg/dl or on being lipid-
lowering medication;
•  low HDL-C: < 40 mg/dl in men and < 50 mg/dl in 
women or being on triglyceride-lowering medication;
•  high blood pressure: systolic pressure ≥ 130 mmHg or 
diastolic pressure ≥ 85 mmHg or on antihypertensive 
medication;
•  high fasting glucose: ≥ 100 mg/dl or being on glucose-
lowering medication.
Statistical analysis
Characteristics of subjects were summarised as mean and 
S.D. for continuous variables and frequency and percent-
age for categorical variables. We examined sociodemo-
graphic and clinical correlates of MetS using a chi-square 
test in the case of categorical variables, performing the 
chotics or mood stabilisers that have been associated with 
weight gain, dyslipidaemia and development of diabetes. 
Longitudinal follow-up studies to estimate changes in MetS 
rates among patients with schizophrenia and bipolar disor-
der suggest that the prevalence of MetS usually increases 
over time, in parallel with duration of illness and treat-
ment 17-19. A recent study from our research group showed 
that MetS rapidly increases from 28.6 to 44.3% over 2 years 
follow-up in a sample of patients with bipolar disorder treat-
ed as usual; moreover, patients developing MetS over time 
were taking antipsychotics at baseline, most of which were 
atypical antipsychotics, confirming the increased risk asso-
ciated with this class of medications 20. In addition to dura-
tion of illness, gender should be another clinical parameter 
that needs to be highlighted in evaluating the risk profile 
of MetS. Few studies have reported higher rates of MetS in 
males with bipolar disorder, with a prevalence of around 
32% in men and 22% in women 21. On the other hand, a 
high prevalence of MetS was noted in women (52%) com-
pared to men (36%) with schizophrenia 8.
While considerable debate exists regarding the causes of 
the high prevalence of metabolic disturbances in patients 
with severe mental illness, gaps remain in relevant as-
pects, encouraging further studies in specific subgroups 
of psychiatric patients to evaluate the impact of each 
variable in developing MetS. Our aim is to identify the 
clinical and sociodemographic features consistently as-
sociated with the occurrence of MetS across different di-
agnostic groups in a sample of patients affected by severe 
and acute mental illnesses.
Materials and Methods
The study had a naturalistic design and involved inpatients 
consecutively admitted to the Psychiatric Inpatient Unit of 
the San Luigi Gonzaga Hospital, Orbassano (University of 
Turin, Italy) from December 2013 to September 2014. 
Subjects
All patients consecutively admitted to the inpatient unit 
were considered for the present study. Patients with a 
main diagnosis of schizophrenia spectrum and other psy-
chotic disorders, bipolar and related disorders, depres-
sive disorders or personality disorders (DSM-5)  22 were 
asked to participate. The aims of the study and study pro-
cedures were thoroughly explained to potential partici-
pants who gave oral consent before participation. Exclu-
sion criteria included age < 18 years, severe and unstable 
general medical conditions, any of the remaining main 
psychiatric diagnoses (e.g. substance related disorders, 
neurodevelopmental disorders, neurocognitive disor-
ders), pregnancy or having just given birth and refusal to 
give consent prior to participating in the study. 
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(±13.51) years; 48% of patients were females; 29.6% had 
schizophrenia spectrum and other psychotic disorders, 
37.6% had bipolar and related disorders, 22.4% had de-
pressive disorders and 10.4% had personality disorders. 
Sociodemographic and clinical characteristics are shown 
in Table I. 
Of the 125 patients, MetS was present in 35.2% of the 
sample. Low HDL-C levels were the most frequently en-
dorsed criterion, present in 57.6% of subjects. Abdominal 
obesity was the second most frequent metabolic abnor-
mality, affecting 51.2% of participants. High triglycerides, 
hypertension and fasting hyperglycaemia were observed 
in 30.4%, 28.8% and 20% of the sample, respectively 
(Table II). 
We divided the sample in two groups according to the 
presence (n = 44) or the absence (n = 81) of MetS crite-
ria. As shown in Figure 1, patients with a main diagnosis 
of schizophrenia spectrum and other psychotic disorders 
and bipolar and related disorders showed a higher rate of 
MetS, respectively 34.1% and 29.5%. MetS was observed 
in 25% of individuals affected by depressive disorders, 
while 11.4% of patients with a main diagnosis of person-
ality disorders met MetS criteria. These differences were 
not statistically significant.
The other sociodemographic and clinical features of the 
Yates correction in the case of a 2×2 table and independ-
ent-samples t tests in the case of continuous variables. In 
order to control for confounding factors, we entered the 
significant independent variables in a stepwise logistic 
regression analysis (LogReg) with MetS as the dependent 
variable. 
Results 
One hundred twenty-five patients were recruited in the 
study. The mean (±S.D.) age of the sample was 44.94 
Table I.
Baseline sociodemographic and clinical characteristics of 
the sample. Caratteristiche socio-demografiche e cliniche del 
campione.
Characteristics Value
Sex, n (%) 
Male
Female
age (years), mean (±SD)
65 (52.0)
60 (48.0)
44.94 (±13.51)
Marital status, n (%) 
Never married
Married
Separated or divorced
Widowed
64 (51.2)
39 (31.2)
16 (12.8)
6 (4.8)
education level (years), mean (±SD) 9.94 (±3.60)
Occupational status, n (%)
Employed full-time
Employed part-time
House-wife
Student 
Unemployed
Retired
Main diagnosis (DSM V), n (%)
Schizophrenia spectrum
Bipolar and related disorders
Depressive disorders
Personality disorders
34 (27.2)
10 (8)
 6 (4.8)
 4 (3.2)
53 (42.4)
18 (14.4)
37 (29.6)
47 (37.6)
28 (22.4)
13 (10.4)
Table II.
Prevalence of MetS (NCEP ATP III modified criteria) and its components. Prevalenza della sindrome metabolica e delle sue 
componenti nel campione.
Criteria n (%) 
Abdominal obesity: > 102 cm (men) or > 88 cm (women) 
Hypertriglyceridaemia: ≥ 150 mg/dl or being on triglyceride-lowering medication
Low HDL-C: < 40 mg/dl (men) or < 50 mg/dl (women) or being on lipid-lowering medication
64 (51.2)
38 (30.4)
72 (57.6)
High blood pressure: ≥ 130 mm systolic or ≥ 85 mm diastolic or being on antihypertensive medication
High fasting glucose: ≥ 100 mg/dl or being on glucose-lowering medication
MetS (three or more criteria)
36 (28.8)
25 (20)
44 (35.2)
FIguRe 1. 
Prevalence of MetS (NCEP ATP III modified criteria) in the main 
different diagnoses of the sample. Prevalenza della sindrome 
metabolica nelle differenti diagnosi principali del campione.
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Table III.
Comparison between patients with MetS (n = 44) and without MetS (n = 81): sociodemographic and clinical characteristics. 
Confronto tra pazienti con MetS (n = 44) e senza MetS (n = 81): caratteristiche socio-demografiche e cliniche.
MetS No MetS p
Sex, n (%)
Male
Female
56.8
43.2
49.4
50.6
0.458
age (years), mean (±SD) 47.09 43.78 0.192
Positive family history for psychiatric disorders, n (%) 34.1 41.8 0.445
Positive family history for bipolar disorder, n (%) 9.1 7.6 0.744
Positive family history for CV disease, n (%) 45.2 38.5 0.560
Positive family history for diabetes, n (%) 19.0 15.4 0.616
educational level (years), mean (±SD) 9.52 10.16 0.346
Occupational status, n (%)
Employed full-time
Employed part-time
House-wife
Student 
Unemployed
Retired
27.3
6.8
4.5
0
47.7
13.6
27.2
8.6
4.9
4.9
39.5
14.8
0.810
White collar
Blue collar
73.3
26.7
80.8
19.2
0.701
Marital status, n (%) 
Never married
Married
Divorced
Separated
Widowed
52.3
29.5
6.8
6.8
4.5
50.6
32.1
2.5
9.9
4.9
0.786
locality, n (%) 
Urban
Rural
2.3
97.7
9.9
90.1
0.158
living arrangement, n (%) 
Family of origin
Own family
Therapeutic facility
Homeless
38.6
50.0
9.1
2.3
38.3
50.6
9.9
1.2
1.000
Current smoking, n (%) 54.5 59.3 0.705
lifetime smoking, n (%) 59.1 61.7 0.849
Current alcohol abuse, n (%) 18.2 4.9 0.025
lifetime alcohol abuse, n (%) 22.7 12.3 0.200
Current substance abuse, n (%) 11.4 8.6 0.752
lifetime substance abuse, n (%) 20.5 21.0 1.000
Main diagnosis (DSM V), n (%)
 Schizophrenia Spectrum
Bipolar and related disorders
Depressive disorders
Personality disorders
27.7
40.5
39.3
38.5
72.3
59.5
60.7
61.5
0.583
(continues)
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MetS No MetS p
Current psychiatric comorbidity, n (%)
Neurodevelopmental disorders
Anxiety disorders
Obsessive compulsive and related disorders
Somatic symptom and related disorders
Feeding and eating disorders
Substance related disorders
Neurocognitive disorders
Personality disorders
0
0
2.3
4.5
0
11.4
2.3
13.6
2.5
1.2
0
1.2
1.2
1.2
0
17.3
0.540
1.000
0.352
0.283
1.000
0.020
0.352
0.799
lifetime psychiatric comorbidity, n (%)
Neurodevelopmental disorders
Depressive disorders
Anxiety disorders
Obsessive compulsive and related disorders
Somatic symptom and related disorders
Feeding and eating disorders
Substance related disorders
Neurocognitive disorders
Personality disorders
34.1
0
2.3
0
2.3
4.5
0
18.2
2.3
18.2
27.2
2.5
0
1.2
0
1.2
1.2
7.4
0
18.5
0.421
0.540
0.352
1.000
0.352
0.283
1.000
0.081
0.352
1.000
age of onset (years), mean (±SD) 31.03 31.70 0.804
Duration of illness (years), mean (±SD) 16.31 11.47 0.034
lifetime aggressiveness, n (%) 56.8 46.9 0.350
lifetime suicide attempted, n (%) 40.9 34.6 0.561
Involuntary treatment, n (%) 9.1 8.6 1.000
Duration of involuntary treatment (years), mean (±SD) 7.00 10.33 0.104
Duration of hospitalisation (years), mean (±SD) 15.56 15.23 0.866
Seasonal admission, n (%)
Autumn
Winter
Spring
Summer
56.8
22.7
6.8
13.6
40.7
40.7
7.4
11.1
0.209
Hospital discharge, n (%)
Ordinary
Patient request
95.5
4.5
98.8
1.2
0.283
Current typical antipsychotic treatment, n (%) 20.5 9.9 0.110
Current atypical antipsychotic treatment, n (%) 59.1 39.5 0.041
Current treatment with mood stabilizers, n (%) 34.1 27.2 0.421
Current treatment with antidepressants, n (%) 38.6 39.5 1.000
Current treatment with anxiolytics, n (%) 52.5 50.6 1.000
lifetime psychiatric treatment, n (%) 95.3 86.4 0.216
lifetime treatment with antipsychotics, n (%) 75.6 62.0 0.157
lifetime treatment with mood stabilisers, n (%) 56.4 39.7 0.115
lifetime treatment with antidepressants, n (%) 63.4 58.2 0.695
lifetime treatment with anxiolytics, n (%) 88.1 72.2 0.065
Physical activity
Absent
Mild (< 4 hours/week)
Moderate (4 hours/week)
Intense (> 4 hours/week)
100
0
0
0
86.4
7.4
1.2
4.9
0.069
Table III - Follows
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with previous studies evaluating inpatients affected by 
psychotic and mood disorders  30  31 and with a recent 
meta-analysis in which no difference was seen in MetS 
in studies directly comparing schizophrenia and bipolar 
disorder, or in those directly comparing bipolar disorder 
to major depressive disorder 32. 
Furthermore, we found no significant differences in the 
prevalence of MetS between men and women. Several 
studies are consistent with our results, indicating that 
both sexes deserve the same attention 9 13. However, other 
studies have reported higher rates of MetS in females, es-
pecially with schizophrenia 8 and recurrent major depres-
sive disorder  33, while higher MetS rates were found in 
young males with bipolar disorder 21. Nevertheless, in the 
bipolar disorder population, the majority of studies have 
reported no differences between sex or do not report on 
it specifically 9.
We found that 59.1% of patients in the MetS subgroup 
were taking atypical antipsychotics (SGAs) compared 
with 39.5% in the subgroup of patients without MetS. 
This difference was statistically significant and confirmed 
by LogReg analysis (p = 0.005). The lower proportion 
of MetS (30%) found by Centorrino and colleagues in a 
sample of antipsychotic-exposed hospitalised patients is 
probably due to the younger mean age of subjects; none-
theless, patients taking antipsychotics presented MetS 
more frequently than those who had never taken antip-
sychotics 30. The association between SGAs and MetS is 
confirmed by several studies in patients with different di-
agnoses. In particular, Correll and colleagues found that 
inpatients with bipolar disorder and schizophrenia who 
are treated with SGAs have similarly high rates of MetS 31.
It must be emphasised that in our study only current use of 
atypical antipsychotics was significantly associated with 
MetS. This is a relevant finding, although current treat-
ment with SGAs could underlie previous antipsychotic 
treatments that are not always easy to retrace, especially 
for length and dosage. However, our results showed that 
exposure to atypical antipsychotics, even for a brief pe-
riod of time, can lead to the development or worsening 
of metabolic dysregulations that can consequently give 
rise to MetS. 
Published data examining changes in weight during short-
term antipsychotic treatment (4-12 weeks) of schizophre-
nia revealed that increases in weight and body mass in-
dex in subjects who received risperidone, amisulpride or 
olanzapine were clinically and statistically significantly 
greater than in those who received placebo 34. Consider-
ing glucose tolerance, Sacher et al. investigated the acute 
effects of oral administration of olanzapine and ziprasi-
done in healthy volunteers and observed a significant de-
crease (p < 0.001) in whole body insulin sensitivity after 
oral intake of olanzapine (10 mg/day) for 10 days 35. 
In conclusion, our study confirms the association between 
two subgroups (with MetS and without MetS) are sum-
marised in Table III. 
Patients who fulfilled MetS definition were more often 
characterised by current atypical antipsychotic treatment 
(59.1% vs 39.5%; p = 0.041), current alcohol abuse 
(18.2% vs 4.9%; p = 0.025), current psychiatric comor-
bidity with substance related disorders (11.4% vs 1.2%; 
p = 0.020) and longer duration of illness (16.31 years vs 
11.47 years; p = 0.034). 
Next, a LogReg analysis was conducted to assess the rela-
tionship between the above-mentioned variables and the 
occurrence of MetS. The following explanatory variables 
were included in the analysis as independent variables: 
current atypical antipsychotic treatment, current alcohol 
abuse, current psychiatric comorbidity with substance re-
lated disorders and duration of illness. The only variable 
significantly associated with the presence of MetS was 
current atypical antipsychotic treatment (p = 0.005). 
Discussion and conclusions
MetS increases the risk for cardiovascular diseases, insu-
lin resistance and diabetes mellitus, and can lead to in-
creased morbidity and mortality, in addition to impairing 
patient adherence to medication24. These are the reasons 
why, in recent years, MetS has emerged as a significant 
problem in both psychiatry and public health. There is 
thus a need to detect high-risk groups for developing 
MetS that should especially be screened and treated. 
This study investigated the sociodemographic and clini-
cal correlates of MetS in a sample of inpatients with ma-
jor psychiatric disorder. More specifically, we highlighted 
whether the risk profile is the same depending on diag-
nostic subgroup, since several original reports as well as 
reviews did not provide unequivocal evidence. Moreo-
ver, we explored whether MetS rates differ depending on 
individual variables such as age, gender, duration of ill-
ness and treatment settings in order to guide clinicians in 
monitoring and treatment decisions.
The sample comprised 125 consecutively recruited hos-
pitalised patients with a main diagnosis of schizophrenia 
spectrum and other psychotic disorders (34.1%), bipolar 
and related disorders (29.5%), depressive disorders (25%) 
or personality disorders (11.4%).
In our sample, the overall prevalence of MetS was 35.2%. 
This result is similar to that reported among patients affect-
ed by schizophrenia spectrum disorders 12 25-27 and mood 
disorders 13 28 29. Nevertheless, this is higher than the preva-
lence of MetS (23.7%) found among hospitalised psychi-
atric patients by Centorrino and colleagues 30. This could 
be due to a younger average age of the study subjects 
(35.7± 13.0 years) than in sample (44.94 ± 13.51 years).
We did not observe a specific psychiatric disorder sig-
nificantly associated with MetS. This finding is in line 
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one year follow-up study. BMC Psychiatry 2007;23:7-14. 
19 Kraemer S, Minarzyk A, Forst T, et al. Prevalence of metabol-
ic syndrome in patients with schizophrenia, and metabolic 
changes after 3 months of treatment with antipsychotics re-
sults from a German observational study. BMC Psychiatry 
2011;11:173. 
20 Salvi V, D’Ambrosio V, Bogetto F, et al. Metabolic syndrome 
in Italian patients with bipolar disorder: A 2-year follow-up 
study. J Affect Disord 2012;136:599-603.
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lence of metabolic syndrome in Italian patients with bipolar 
disorders. Psychiatry Clin Neurosci 2011;65:47-54. 
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cal Manual of Mental Disorders. 5th edition. Arlington, VA: 
American Psychiatric Association 2013. 
23 Bo S, Ciccone G, Pearce N, et al. Prevalence of undiagnosed 
treatment with SGAs and increased risk of MetS among 
psychiatric patients independently of the diagnosis and 
other clinical features. Our findings are in agreement 
with those reported in a recent meta-analysis, although 
our study was conducted in an Italian sample of acute 
inpatients 32. These conclusions suggest a shared suscep-
tibility to antipsychotic-related metabolic dysregulations 
that is not primarily related to psychiatric diagnosis or 
concomitant to other psychiatric treatment. 
The limitations of the present study include its observa-
tional nature and the relatively small sample size, espe-
cially regarding individuals primarily affected by per-
sonality disorders. Therefore, our conclusions are to be 
considered as suggestive. However, the alarmingly high 
frequency of MetS in all diagnostic subgroups and its rele-
vant association with current atypical antipsychotic treat-
ment warrant further analyses of risk factors in patients 
with major mental disorders in order to administer safer 
and better-tolerated treatments, giving particular atten-
tion when using atypical antipsychotics that are known 
for their metabolic side effects, and preventive programs 
targeting general health among psychiatric patients. 
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